Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity.
Adolescent
Adult
Age Factors
Aged
Antibodies, Viral
/ blood
Antibody Formation
B-Lymphocytes
/ immunology
COVID-19
/ genetics
COVID-19 Vaccines
/ immunology
Cohort Studies
Coronavirus Nucleocapsid Proteins
/ immunology
Female
Humans
Immunization, Secondary
Immunogenicity, Vaccine
Immunoglobulin G
/ blood
Immunosuppressive Agents
/ therapeutic use
Lymphocyte Count
Male
Middle Aged
Phosphoproteins
/ immunology
Polyendocrinopathies, Autoimmune
/ drug therapy
Rituximab
/ therapeutic use
SARS-CoV-2
/ physiology
Seroconversion
Spike Glycoprotein, Coronavirus
/ immunology
T-Lymphocytes
/ immunology
Young Adult
COVID-19 Drug Treatment
COVID-19
JAK inhibitors
SARS-CoV-2
adverse events
antibody response
immune suppressants
immunomodulators
inborn errors of immunity
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
30
06
2021
revised:
19
08
2021
accepted:
24
08
2021
pubmed:
8
9
2021
medline:
24
11
2021
entrez:
7
9
2021
Statut:
ppublish
Résumé
SARS-CoV-2 vaccination is recommended in patients with inborn errors of immunity (IEIs); however, little is known about immunogenicity and safety in these patients. We sought to evaluate the impact of genetic diagnosis, age, and treatment on antibody response to COVID-19 vaccine and related adverse events in a cohort of patients with IEIs. Plasma was collected from 22 health care worker controls, 81 patients with IEIs, and 2 patients with thymoma; the plasma was collected before immunization, 1 to 6 days before the second dose of mRNA vaccine, and at a median of 30 days after completion of the immunization schedule with either mRNA vaccine or a single dose of Johnson & Johnson's Janssen vaccine. Anti-spike (anti-S) and anti-nucleocapsid antibody titers were measured by using a luciferase immunoprecipitation systems method. Information on T- and B-cell counts and use of immunosuppressive drugs was extracted from medical records, and information on vaccine-associated adverse events was collected after each dose. Anti-S antibodies were detected in 27 of 46 patients (58.7%) after 1 dose of mRNA vaccine and in 63 of 74 fully immunized patients (85.1%). A lower rate of seroconversion (7 of 11 [63.6%]) was observed in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Previous use of rituximab and baseline counts of less than 1000 CD3 Vaccinating patients with IEIs is safe, but immunogenicity is affected by certain therapies and gene defects. These data may guide the counseling of patients with IEIs regarding prevention of SARS-CoV-2 infection and the need for subsequent boosts.
Sections du résumé
BACKGROUND
SARS-CoV-2 vaccination is recommended in patients with inborn errors of immunity (IEIs); however, little is known about immunogenicity and safety in these patients.
OBJECTIVE
We sought to evaluate the impact of genetic diagnosis, age, and treatment on antibody response to COVID-19 vaccine and related adverse events in a cohort of patients with IEIs.
METHODS
Plasma was collected from 22 health care worker controls, 81 patients with IEIs, and 2 patients with thymoma; the plasma was collected before immunization, 1 to 6 days before the second dose of mRNA vaccine, and at a median of 30 days after completion of the immunization schedule with either mRNA vaccine or a single dose of Johnson & Johnson's Janssen vaccine. Anti-spike (anti-S) and anti-nucleocapsid antibody titers were measured by using a luciferase immunoprecipitation systems method. Information on T- and B-cell counts and use of immunosuppressive drugs was extracted from medical records, and information on vaccine-associated adverse events was collected after each dose.
RESULTS
Anti-S antibodies were detected in 27 of 46 patients (58.7%) after 1 dose of mRNA vaccine and in 63 of 74 fully immunized patients (85.1%). A lower rate of seroconversion (7 of 11 [63.6%]) was observed in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Previous use of rituximab and baseline counts of less than 1000 CD3
CONCLUSION
Vaccinating patients with IEIs is safe, but immunogenicity is affected by certain therapies and gene defects. These data may guide the counseling of patients with IEIs regarding prevention of SARS-CoV-2 infection and the need for subsequent boosts.
Identifiants
pubmed: 34492260
pii: S0091-6749(21)01356-7
doi: 10.1016/j.jaci.2021.08.016
pmc: PMC8418380
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Coronavirus Nucleocapsid Proteins
0
Immunoglobulin G
0
Immunosuppressive Agents
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1192-1197Informations de copyright
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Références
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
J Clin Immunol. 2021 Oct;41(7):1479-1489
pubmed: 34164762
Ann Allergy Asthma Immunol. 2021 Sep;127(3):383-384
pubmed: 34022388
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
J Allergy Clin Immunol. 2021 Sep;148(3):739-749
pubmed: 34087242
J Allergy Clin Immunol Pract. 2021 Jan;9(1):490-493.e2
pubmed: 33039649
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33890986
Blood. 2021 Sep 23;138(12):1019-1033
pubmed: 33876203
J Clin Immunol. 2021 Oct;41(7):1463-1478
pubmed: 34114122
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2904-2906.e2
pubmed: 33894392
Clin Immunol. 2010 Jun;135(3):412-21
pubmed: 20226738
J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1
pubmed: 33338534
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Int J Mol Sci. 2018 Dec 20;20(1):
pubmed: 30577453
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Transplantation. 2021 Jan 1;105(1):37-55
pubmed: 33148977
J Exp Med. 2010 Jan 18;207(1):155-71
pubmed: 20048285